News for SeaStar Medical Holding Corp Stock (ICU)

SeaStar Medical Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewsWire • 07/11/24

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of SeaStar Medical Holding Corporation (ICU) on Behalf of Investors

Business Wire • 07/11/24

ICU Investors Are Presented With The Chance To Spearhead SeaStar Medical Holding Corporation Securities Fraud Legal Action With The Schall Law Firm

Accesswire • 07/11/24

ICU Investors Have Opportunity to Lead SeaStar Medical Holding Corporation. Securities Fraud Lawsuit

PRNewsWire • 07/10/24

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of SeaStar Medical Holding Corporation (ICU) on Behalf of Investors

Business Wire • 07/10/24

SeaStar Medical Holding Corporation Investors: Robbins LLP Reminds Shareholders of the SeaStar Medical Holding Corporation (ICU) Class Action

Business Wire • 07/10/24

The Law Offices of Frank R. Cruz Announces Investigation of SeaStar Medical Holding Corporation (ICU) on Behalf of Investors

Business Wire • 07/10/24

SEASTAR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against SeaStar Medical Holding Corporation and Encourages Investors to Contact the Firm

GlobeNewsWire • 07/10/24

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against SeaStar Medical Holding Corporation

GlobeNewsWire • 07/09/24

Shareholder Alert: Robbins LLP Informs Stockholders of the Class Action Filed Against SeaStar Medical Holding Corporation (ICU)

GlobeNewsWire • 07/09/24

Rosen Law Firm Urges SeaStar Medical Holding Corporation (ICU, ICUCW) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Business Wire • 07/09/24

Class Action Lawsuit Filed on Behalf of SeaStar Medical Holding Corporation (ICU) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

GlobeNewsWire • 07/08/24

SeaStar Medical Finalizes FDA Labeling Requirement for QUELIMMUNE, Paving the Way for First Commercial Sales as Humanitarian Use Device

GlobeNewsWire • 07/03/24

SeaStar Medical's Selective Cytopheretic Device Featured in Two Presentations at the 42nd Vicenza Course AKI-CRT-ECOS and Critical Care Nephrology

GlobeNewsWire • 06/11/24

SeaStar Medical Strengthens Board of Directors and Transitions to Commercial-Stage Company

GlobeNewsWire • 06/10/24

Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical's Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation

GlobeNewsWire • 06/07/24

SeaStar Medical to Present at the Virtual Emerging Growth Conference on June 12, 2024

GlobeNewsWire • 06/06/24

SeaStar Medical Announces 25-for-1 Reverse Stock Split

GlobeNewsWire • 06/06/24

Manuscript Published on Multiorgan Failure Patients Treated with SeaStar Medical's Selective Cytopheretic Device Who Achieved Transplant Eligibility

GlobeNewsWire • 05/22/24

SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure

GlobeNewsWire • 04/30/24

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeaStar Medical Holding Corporation - ICU

PRNewsWire • 04/28/24

SeaStar Medical Reports 2023 Financial Results and Provides a Business Update

GlobeNewsWire • 04/17/24

SeaStar Medical to Present at the Noble Capital Markets' Emerging Growth Virtual Healthcare Equity Conference

GlobeNewsWire • 04/11/24

SeaStar Medical to Restate Financials, Sets Business Update Call for April 17

GlobeNewsWire • 03/27/24

SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients

GlobeNewsWire • 03/12/24